{"title":"177Lu-PSMA-617可延长抗类固醇药物无效mCRPC患者的无进展生存期","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00970-z","DOIUrl":null,"url":null,"abstract":"<p>A new phase III, randomized, controlled trial was carried out to assess the efficacy of <sup>177</sup>Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC). A total of 468 patients with PSMA<sup>+</sup> mCRPC who experienced disease progression after receiving an androgen receptor pathway inhibitor (ARPI) were randomly allocated to receive <sup>177</sup>Lu-PSMA-617 or a different ARPI. Treatment with <sup>177</sup>Lu-PSMA-617 resulted in improved median radiographic progression-free survival (PFS) compared with a change of ARPI (11.60 months (95% CI 9.30–14.19) versus 5.59 months (95% CI 4.21–5.95)), with a good safety profile. These results showed that <sup>177</sup>Lu-PSMA-617 prolonged radiographic PFS and could be a valid therapeutic alternative for patients considered for a change of ARPI.</p>","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"105 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC\",\"authors\":\"Maria Chiara Masone\",\"doi\":\"10.1038/s41585-024-00970-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A new phase III, randomized, controlled trial was carried out to assess the efficacy of <sup>177</sup>Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC). A total of 468 patients with PSMA<sup>+</sup> mCRPC who experienced disease progression after receiving an androgen receptor pathway inhibitor (ARPI) were randomly allocated to receive <sup>177</sup>Lu-PSMA-617 or a different ARPI. Treatment with <sup>177</sup>Lu-PSMA-617 resulted in improved median radiographic progression-free survival (PFS) compared with a change of ARPI (11.60 months (95% CI 9.30–14.19) versus 5.59 months (95% CI 4.21–5.95)), with a good safety profile. These results showed that <sup>177</sup>Lu-PSMA-617 prolonged radiographic PFS and could be a valid therapeutic alternative for patients considered for a change of ARPI.</p>\",\"PeriodicalId\":12,\"journal\":{\"name\":\"ACS Chemical Health & Safety\",\"volume\":\"105 1\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Chemical Health & Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41585-024-00970-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Health & Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41585-024-00970-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
摘要
我们开展了一项新的III期随机对照试验，以评估177Lu-PSMA-617对他汀类药物无效的转移性抗性前列腺癌（mCRPC）患者的疗效。共有468名PSMA+ mCRPC患者在接受雄激素受体通路抑制剂（ARPI）治疗后出现疾病进展，他们被随机分配接受177Lu-PSMA-617或另一种ARPI治疗。与更换ARPI相比，177Lu-PSMA-617治疗可改善中位放射学无进展生存期（PFS）（11.60个月（95% CI 9.30-14.19）对5.59个月（95% CI 4.21-5.95）），且安全性良好。这些结果表明，177Lu-PSMA-617可延长放射学PFS，可作为考虑更换ARPI的患者的有效替代治疗方法。
177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC
A new phase III, randomized, controlled trial was carried out to assess the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC). A total of 468 patients with PSMA+ mCRPC who experienced disease progression after receiving an androgen receptor pathway inhibitor (ARPI) were randomly allocated to receive 177Lu-PSMA-617 or a different ARPI. Treatment with 177Lu-PSMA-617 resulted in improved median radiographic progression-free survival (PFS) compared with a change of ARPI (11.60 months (95% CI 9.30–14.19) versus 5.59 months (95% CI 4.21–5.95)), with a good safety profile. These results showed that 177Lu-PSMA-617 prolonged radiographic PFS and could be a valid therapeutic alternative for patients considered for a change of ARPI.
期刊介绍：
The Journal of Chemical Health and Safety focuses on news, information, and ideas relating to issues and advances in chemical health and safety. The Journal of Chemical Health and Safety covers up-to-the minute, in-depth views of safety issues ranging from OSHA and EPA regulations to the safe handling of hazardous waste, from the latest innovations in effective chemical hygiene practices to the courts'' most recent rulings on safety-related lawsuits. The Journal of Chemical Health and Safety presents real-world information that health, safety and environmental professionals and others responsible for the safety of their workplaces can put to use right away, identifying potential and developing safety concerns before they do real harm.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
